Does Medicare Cover Leukemia Treatment

Does Medicare cover leukemia treatment in 2026? Leukemia — cancer of the blood and bone marrow — is predominantly a disease of older adults with the majority of cases occurring in people over 65. The four main types of leukemia — acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL) — each require different treatment approaches ranging from oral targeted therapies through intensive chemotherapy and bone marrow transplantation. The good news is that yes — does Medicare cover leukemia treatment in 2026 — comprehensively across all types and treatment modalities. In this complete guide we explain exactly what Medicare covers for leukemia treatment in 2026. All information is sourced from Medicare.gov and CMS.gov.

Also Read —

Does Medicare Cover Cancer Treatment 2026
Medicare Income Limits and IRMAA Surcharges 2026 — Complete Guide
Medicare Part B vs Part D Drug Coverage 2026

Table of Contents

What You Will Learn — Does Medicare Cover Leukemia

Does Medicare cover leukemia treatment in 2026
Does Medicare cover CLL treatment — Imbruvica Venclexta Calquence
Does Medicare cover CML treatment — Gleevec Sprycel Tasigna
Does Medicare cover AML treatment
Does Medicare cover bone marrow transplant for leukemia
Does Medicare cover CAR-T cell therapy for leukemia
How much does leukemia treatment cost with Medicare
Does Medicare Advantage cover leukemia
Frequently asked questions about Medicare leukemia coverage 2026

Does Medicare Cover Leukemia Treatment in 2026?

Yes — does Medicare cover leukemia treatment in 2026 — comprehensively across all four major types of leukemia. Medicare Part D covers oral targeted therapies including ibrutinib (Imbruvica), venetoclax (Venclexta), acalabrutinib (Calquence), imatinib (Gleevec), and dasatinib (Sprycel). Medicare Part B covers IV chemotherapy infusions, monoclonal antibody infusions, CAR-T cell therapy, and related procedures. Medicare Part A covers hospitalization for intensive chemotherapy and bone marrow transplantation.

Leukemia treatment has been transformed by targeted oral therapies — particularly for CLL and CML — allowing many patients to manage their disease with daily oral medications rather than intensive chemotherapy. Medicare’s $2,000 annual Part D out-of-pocket maximum is critically important for leukemia patients taking oral targeted therapies that can cost $10,000 to $20,000 per month at retail prices.

leukemia treatments medicare covers 2026 imbruvica venclexta transplant CAR-T chemotherapy

Does Medicare Cover CLL Treatment?

Does Medicare cover chronic lymphocytic leukemia (CLL) treatment in 2026? Yes — Medicare covers the full range of CLL treatments including the newer targeted oral therapies that have transformed CLL management.

BTK Inhibitors for CLL — Part D

Bruton’s tyrosine kinase inhibitors are the most important class of drugs for CLL treatment:

Ibrutinib (Imbruvica) — covered Part D:

First-generation BTK inhibitor — foundational CLL drug
Retail cost approximately $14,000 to $17,000 per month
$2,000 annual Part D maximum — saves $166,000 to $202,000 per year

Acalabrutinib (Calquence) — covered Part D:

Second-generation BTK inhibitor — fewer side effects than ibrutinib
Retail cost approximately $13,000 to $16,000 per month
$2,000 annual Part D maximum — saves $154,000 to $190,000 per year

Zanubrutinib (Brukinsa) — covered Part D:

Third-generation BTK inhibitor
Retail cost approximately $13,000 to $15,000 per month
$2,000 annual Part D maximum

BCL-2 Inhibitor for CLL — Part D

Venetoclax (Venclexta) — covered Part D:

BCL-2 inhibitor for CLL — used as monotherapy or combination
Retail cost approximately $9,000 to $12,000 per month
$2,000 annual Part D maximum — saves $106,000 to $142,000 per year

PI3K Inhibitors for CLL — Part D

Idelalisib (Zydelig) — covered Part D
Duvelisib (Copiktra) — covered Part D

Monoclonal Antibodies for CLL — Part B

IV monoclonal antibodies administered in infusion centers — covered Part B at 80% after deductible:

Obinutuzumab (Gazyva) — anti-CD20 — covered Part B
Rituximab (Rituxan) — anti-CD20 — covered Part B
Ofatumumab (Arzerra) — anti-CD20 — covered Part B

With Medigap Plan G — all CLL monoclonal antibody infusions cost $0 after the annual deductible.

Venetoclax Plus Obinutuzumab — Comprehensive Coverage

The combination of venetoclax (Part D) plus obinutuzumab (Part B) — a standard first-line CLL regimen — is comprehensively covered through both Medicare pathways. Venetoclax subject to $2,000 Part D cap and obinutuzumab covered at $0 with Plan G after deductible.

Does Medicare Cover CML Treatment?

Does Medicare cover chronic myeloid leukemia (CML) treatment in 2026? Yes — Medicare Part D covers the oral tyrosine kinase inhibitors (TKIs) that have transformed CML from a fatal disease to a manageable chronic condition.

TKI Therapies for CML — Part D

First-generation TKI:

Imatinib (Gleevec) — covered Part D — generic now available significantly reducing cost — approximately $100 to $500 per month with generic — from $9,000 per month brand

Second-generation TKIs:

Dasatinib (Sprycel) — covered Part D — retail approximately $10,000 to $13,000 per month — $2,000 annual Part D cap
Nilotinib (Tasigna) — covered Part D — retail approximately $10,000 to $13,000 per month — $2,000 annual Part D cap
Bosutinib (Bosulif) — covered Part D — $2,000 annual Part D cap

Third-generation TKIs:

Ponatinib (Iclusig) — covered Part D — for T315I mutation — $2,000 annual cap
Asciminib (Scemblix) — covered Part D — STAMP inhibitor — $2,000 annual cap

Generic Imatinib — Most Affordable CML Treatment

The availability of generic imatinib (Gleevec) has dramatically reduced CML treatment costs for Medicare beneficiaries. Generic imatinib costs approximately $100 to $500 per month under Part D — making CML maintenance extraordinarily affordable for patients responding to first-line therapy.

BCR-ABL Testing — Covered at $0

PCR testing for BCR-ABL mutation levels — the primary monitoring test for CML treatment response — is covered as a diagnostic laboratory test at $0.

Does Medicare Cover AML Treatment?

Does Medicare cover acute myeloid leukemia (AML) treatment in 2026? Yes — Medicare covers the full spectrum of AML treatments including conventional chemotherapy and newer targeted agents.

Conventional AML Induction Chemotherapy — Part B and Part A

Standard AML induction chemotherapy — typically cytarabine plus an anthracycline (7+3 regimen) — involves intensive IV chemotherapy administered during hospitalization:

Cytarabine (Ara-C) — covered Part B and Part A
Daunorubicin — covered Part B and Part A
Idarubicin — covered Part B and Part A

AML induction typically requires 4 to 6 weeks of hospitalization — covered under Medicare Part A with the $1,676 deductible per benefit period. Medigap Plan G covers this deductible.

Targeted AML Therapies — Part D and Part B

Midostaurin (Rydapt) — FLT3 inhibitor — covered Part D — $2,000 annual cap
Gilteritinib (Xospata) — FLT3 inhibitor — covered Part D — $2,000 annual cap
Venetoclax (Venclexta) — BCL-2 inhibitor — covered Part D — $2,000 annual cap — used with azacitidine for older AML patients
Enasidenib (Idhifa) — IDH2 inhibitor — covered Part D
Enasidenib plus azacitidine — Part D and Part B combination
Ivosidenib (Tibsovo) — IDH1 inhibitor — covered Part D
Gemtuzumab ozogamicin (Mylotarg) — CD33-targeted antibody-drug conjugate — covered Part B
Glasdegib (Daurismo) — covered Part D
CPX-351 (Vyxeos) — liposomal cytarabine daunorubicin — covered Part B

Azacitidine and Decitabine — Part B

Hypomethylating agents for older AML patients — covered Part B at 80% after deductible:

Azacitidine (Vidaza) — IV or subcutaneous — covered Part B
Decitabine (Dacogen) — covered Part B

With Medigap Plan G — all IV AML treatments cost $0 after the annual deductible.

Does Medicare Cover ALL Treatment?

Does Medicare cover acute lymphoblastic leukemia (ALL) treatment in 2026? Yes — Medicare covers ALL treatment across all treatment phases.

ALL Induction Chemotherapy — Covered

Multi-drug induction chemotherapy for ALL — covered Part B and Part A.

Tyrosine Kinase Inhibitors for Ph+ ALL — Part D

Imatinib — generic covered Part D — very affordable
Dasatinib — covered Part D — $2,000 annual cap
Ponatinib — covered Part D — for high-risk Ph+ ALL

Targeted Therapies for ALL — Part B

Inotuzumab ozogamicin (Besylomi) — CD22-targeted — covered Part B
Blinatumomab (Blincyto) — bispecific T-cell engager — covered Part B
Asparaginase products — covered Part B

Does Medicare Cover Bone Marrow Transplant for Leukemia?

Does Medicare cover bone marrow transplant (hematopoietic stem cell transplantation) for leukemia in 2026? Yes — Medicare covers both autologous and allogeneic stem cell transplantation for qualifying leukemia patients at Medicare-approved transplant centers.

Allogeneic Stem Cell Transplant — Covered

Allogeneic transplant using donor stem cells — the most commonly used transplant for leukemia — covered under Medicare Part A for inpatient hospitalization. Coverage includes:

Pre-transplant evaluation and conditioning chemotherapy
The stem cell infusion procedure
Post-transplant hospitalization
Post-transplant follow-up and graft-versus-host disease management

Autologous Stem Cell Transplant — Covered

Autologous transplant using the patient’s own stem cells — covered for appropriate leukemia indications.

Transplant Center Requirements

Medicare covers stem cell transplantation only at Medicare-approved transplant centers. Most major academic medical centers performing transplants are Medicare-approved.

Transplant Costs with Medicare

Bone marrow transplant hospitalization is extremely expensive — often $200,000 to $500,000 or more. Medicare Part A covers the inpatient hospitalization after the $1,676 deductible per benefit period.

With Medigap Plan G — the entire transplant hospitalization costs $0 after the $257 annual Part B deductible — covering the $1,676 Part A deductible and all extended hospital stay coinsurance. This is one of the most significant financial benefits of Medigap Plan G for any Medicare condition.

Does Medicare Cover CAR-T Cell Therapy for Leukemia?

Does Medicare cover CAR-T cell therapy for leukemia in 2026? Yes — Medicare covers FDA-approved CAR-T cell therapies for qualifying leukemia patients.

CAR-T Coverage for Leukemia

Tisagenlecleucel (Kymriah) — covered for relapsed/refractory B-cell ALL in patients up to 25 years — Medicare may cover for adult ALL

CAR-T cell therapy is administered in inpatient or outpatient settings and covered through Medicare Part B or Part A depending on administration setting.

CAR-T cell therapy costs $400,000 to $600,000 per treatment course — one of the most expensive treatments in all of medicine. Medicare coverage with Medigap Plan G provides extraordinary financial protection for eligible patients.

Does Medicare Cover Leukemia Monitoring?

Does Medicare cover laboratory monitoring for leukemia in 2026? Yes — Medicare covers all major leukemia monitoring tests.

Blood Tests — Covered at $0

Complete blood count with differential — covered at $0 — the primary monitoring test for all leukemia types.

PCR Testing — Covered at $0 or 80%

BCR-ABL quantitative PCR for CML — covered as diagnostic laboratory at $0. MRD (minimal residual disease) testing — covered for monitoring treatment response.

Bone Marrow Biopsy — Covered

Bone marrow aspiration and biopsy — covered at 80% after deductible for diagnosis and monitoring.

Flow Cytometry — Covered

Flow cytometry for immunophenotyping of leukemia cells — covered as diagnostic laboratory.

CLL targeted therapy medicare $2000 cap 2026 imbruvica calquence venclexta savings annual

How Much Does Leukemia Treatment Cost with Medicare in 2026?

CLL Oral Targeted Therapy

Imbruvica ibrutinib — $2,000 annual Part D maximum — saves $166,000 to $202,000 annually Calquence acalabrutinib — $2,000 annual Part D maximum — saves $154,000 to $190,000 Venclexta venetoclax — $2,000 annual Part D maximum — saves $106,000 to $142,000

CML Oral Targeted Therapy

Generic imatinib — approximately $100 to $500 per month — very affordable Sprycel Tasigna — $2,000 annual Part D maximum

AML Hospitalization

Induction chemotherapy hospitalization — $1,676 Part A deductible With Medigap Plan G — $0 after annual deductible

IV Monoclonal Antibodies — CLL

Obinutuzumab rituximab — 20% Part B coinsurance without supplement With Medigap Plan G — $0 after annual deductible

Bone Marrow Transplant

Without supplement — $1,676 deductible plus potential extended stay costs With Medigap Plan G — $0 after annual deductible

CAR-T Cell Therapy

$400,000 to $600,000 total — Medicare covers with Medigap Plan G at $0 after deductible

bone marrow transplant medicare coverage 2026 leukemia medigap plan g savings cost

Does Medicare Advantage Cover Leukemia?

Does Medicare Advantage cover leukemia treatment in 2026? Yes — all Medicare Advantage plans must cover leukemia treatment.

Prior authorization — required for oral targeted therapies and CAR-T cell therapy. In-network leukemia specialist and cancer center — verify before treatment. Annual maximum $9,350 — most leukemia patients on intensive treatment reach this quickly. Part D $2,000 maximum — same critical protection for oral TKIs and BTK inhibitors.

Frequently Asked Questions — Does Medicare Cover Leukemia

Does Medicare cover leukemia treatment in 2026?

Yes — does Medicare cover leukemia comprehensively in 2026 including oral BTK inhibitors ibrutinib and acalabrutinib under Part D with $2,000 annual cap, venetoclax BCL-2 inhibitor under Part D, CML TKIs including generic imatinib and dasatinib, AML chemotherapy and targeted therapy, monoclonal antibody infusions under Part B, bone marrow transplantation, and CAR-T cell therapy. With Medigap Plan G most IV leukemia treatment costs $0 after the annual deductible.

Does Medicare cover Imbruvica for CLL?

Yes — Medicare Part D covers ibrutinib (Imbruvica) for CLL. Imbruvica costs approximately $14,000 to $17,000 per month at retail. The $2,000 annual Part D out-of-pocket maximum saves CLL patients $166,000 to $202,000 annually — one of the most extraordinary Medicare drug benefit savings for any condition.

Does Medicare cover Venclexta for CLL?

Yes — Medicare Part D covers venetoclax (Venclexta) for CLL and AML. Venclexta costs approximately $9,000 to $12,000 per month at retail. The $2,000 annual Part D cap saves patients $106,000 to $142,000 annually.

Does Medicare cover bone marrow transplant for leukemia?

Yes — Medicare covers allogeneic and autologous stem cell transplantation for qualifying leukemia patients at Medicare-approved transplant centers. The $1,676 Part A deductible applies per benefit period. With Medigap Plan G the entire transplant hospitalization costs $0 after the annual deductible.

Does Medicare cover generic imatinib for CML?

Yes — Medicare Part D covers generic imatinib (generic Gleevec) for CML at very affordable prices — approximately $100 to $500 per month — dramatically less than brand Gleevec at approximately $9,000 per month. Generic imatinib makes CML maintenance among the most affordable cancer treatments under Medicare.

Summary — Does Medicare Cover Leukemia 2026

Does Medicare cover leukemia treatment in 2026? Yes — Medicare provides extraordinary comprehensive leukemia coverage across all four major types — CLL, CML, AML, and ALL. The financial protections are among the most significant in all of Medicare — the $2,000 annual Part D cap saves CLL patients up to $202,000 annually on ibrutinib and the combination of Medigap Plan G plus the $2,000 Part D cap makes even bone marrow transplantation and CAR-T cell therapy financially manageable.

For leukemia patients taking oral targeted therapies the $2,000 annual Part D maximum is the most important Medicare financial benefit available — providing protection from medications that would otherwise cost $100,000 to $200,000 per year at retail. Leukemia patients represent the group that benefits most dramatically from Medicare’s Part D annual cap in all of Medicare.

For free help understanding your Medicare leukemia coverage contact your State Health Insurance Assistance Program (SHIP) at shiphelp.org or call Medicare free at 1-800-633-4227.

This guide is for informational purposes only. Always consult your hematologist and oncologist and verify current Medicare coverage at Medicare.gov.

Sources: Medicare.gov | CMS.gov | SSA.gov | AARP.org

Last updated: April 2026 | Author: James Carter, Independent Medicare Research Analyst

Does Medicare Cover Leukemia Treatment — Complete Guide 2026

What You Will Learn — Does Medicare Cover Leukemia